Advent of a New Generation of Antimigraine Medications

摘要: This chapter will address recent developments in the treatment of migraine. The promising clinical trials using a new antimigraine medication, BIBN4096BS, heralds advent generation therapeutics. BIBN4096BS targets receptor for neuropeptide calcitonin gene–related peptide (CGRP), which appears to play causal role migraine pain. We discuss rationale and therapeutic implications modulating CGRP, including its potential acting at multiple sites trigeminovasculature. then currently used acute preventative pharmacological treatments. Of particular interest is increasing evidence that antiepileptic drugs may be an effective prophylactic Future strategies selectively downregulate CGRP synthesis use other forms trigeminal-mediated pain, such as temporomandibular disorder trigeminal neuralgia, explored. Keywords: calcitonin gene-related (CGRP); migraine; triptan; trigeminal ganglion; anti-epileptic; CGRP antagonist; neurogenic inflammation; neuropeptide; neurovascular headache; pathophysiologic mechanisms; acute therapies; preventive therapies